Chimmitecan is a potent topoisomerase I inhibitor. Chimmitecan is also an active metabolite of simmitecan. Chimmitecan displays outstanding activity in vitro and in vivo. The substitution at the 9-position benefits chimmitecan a salient anti-MDR activity, stability in human serum albumin, improved solubility, and oral availability, which might favorably promise its therapeutic potential in clinical settings. Source summary: Chimmitecan, a camptothecin derivative, acts as a topoisomerase I-inhibiting ADC payload for tumor-selective chemotherapy.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Topoisomerase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.